---
figid: PMC1860037__gt83121.f1
figlink: /pmc/articles/PMC1860037/figure/fig1/
number: <b>Figure 1</b>
caption: Interleukin 6 (IL‐6) can bind to both the soluble (s) and membrane bound
  (m) forms of the IL‐6 receptor (IL‐6R). On binding of IL‐6, both forms of IL‐6R
  can activate gp130 and subsequent downstream signalling pathways. The classic activation
  pathway (A) involves dimerisation of membrane bound IL‐6R with gp130. (B) In tissues
  where membrane bound IL‐6R is not expressed, soluble IL‐6R (sIL‐6R) can trigger
  gp130. This trans‐signalling is therefore responsive to localised concentrations
  of sIL‐6R. When triggered, gp130 activates Janus kinase (JAK) receptor associated
  kinases, which phosphorylate gp130 and thereby regulate the activity of STAT1/3
  and the SHP2 cascade. Among other effects, this triggers negative regulators of
  these signalling pathways, including suppressor of cytokine signalling (SOCS)‐1
  and SOCS3. (C) Soluble gp130 (sgp130) can bind to sIL‐6R and prevent its interaction
  with membrane bound gp130. This effectively prevents activation of gp130 and subsequent
  downstream signalling events.
pmcid: PMC1860037
papertitle: 'Role of interleukin 6 in a murine model of Crohn''s ileitis: are cytokine/anticytokine
  strategies the future for IBD therapies?.'
reftext: T T Pizarro, et al. Gut. 2006 Sep;55(9):1226-1227.
pmc_ranked_result_index: '40485'
pathway_score: 0.953103
filename: gt83121.f1.jpg
figtitle: 'Role of interleukin 6 in a murine model of Crohn''s ileitis: are cytokine/anticytokine
  strategies the future for IBD therapies?'
year: '2006'
organisms: Homo sapiens
ndex: c5a3d638-deef-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC1860037__gt83121.f1.html
  '@type': Dataset
  description: Interleukin 6 (IL‐6) can bind to both the soluble (s) and membrane
    bound (m) forms of the IL‐6 receptor (IL‐6R). On binding of IL‐6, both forms of
    IL‐6R can activate gp130 and subsequent downstream signalling pathways. The classic
    activation pathway (A) involves dimerisation of membrane bound IL‐6R with gp130.
    (B) In tissues where membrane bound IL‐6R is not expressed, soluble IL‐6R (sIL‐6R)
    can trigger gp130. This trans‐signalling is therefore responsive to localised
    concentrations of sIL‐6R. When triggered, gp130 activates Janus kinase (JAK) receptor
    associated kinases, which phosphorylate gp130 and thereby regulate the activity
    of STAT1/3 and the SHP2 cascade. Among other effects, this triggers negative regulators
    of these signalling pathways, including suppressor of cytokine signalling (SOCS)‐1
    and SOCS3. (C) Soluble gp130 (sgp130) can bind to sIL‐6R and prevent its interaction
    with membrane bound gp130. This effectively prevents activation of gp130 and subsequent
    downstream signalling events.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HRAS
  - KRAS
  - IL6
  - NRAS
  - PIK3R3
  - MAPK1
  - GRB2
  - JAK1
  - PIK3CD
  - MAPK3
  - IL6R
  - PTPN11
  - SOCS1
  - PIK3R5
  - AKT3
  - PIK3R4
  - PIK3CA
  - SOCS3
  - AKT2
  - JAK3
  - PIK3CB
  - PIK3R6
  - AKT1
  - TYK2
  - PIK3CG
  - STAT3
  - JAK2
  - Cancer
genes:
- word: Ras/ERK
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras/ERK
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: =IL-6
  symbol: IL6
  source: hgnc_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: Ras/ERK
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: AktRas/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: Grb2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: AktRas/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: IL-6R
  symbol: IL6R
  source: hgnc_symbol
  hgnc_symbol: IL6R
  entrez: '3570'
- word: SHP2
  symbol: SHP-2
  source: hgnc_alias_symbol
  hgnc_symbol: PTPN11
  entrez: '5781'
- word: SOCS1
  symbol: SOCS1
  source: hgnc_symbol
  hgnc_symbol: SOCS1
  entrez: '8651'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: SOCS3
  symbol: SOCS3
  source: hgnc_symbol
  hgnc_symbol: SOCS3
  entrez: '9021'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
